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Abstract
Background: The CHAVI002 study was designed to characterize immune responses, particularly HIV-specific T-cell
responses, amongst 2 cohorts of HIV-exposed seronegative (HESN) individuals. The absence of a clear definition of HESNs
has impaired comparison of research within and between such cohorts. This report describes two distinct HESN cohorts and
attempts to quantify HIV exposure using a ‘HIV risk index’ (RI) model.
Methods: HIV serodiscordant couples (UK; 24, Uganda; 72) and HIV unexposed seronegative (HUSN) controls (UK; 14,
Uganda; 26 couples, 3 individuals) completed sexual behavior questionnaires every 3 months over a 9 month period. The
two cohorts were heterogeneous, with most HESNs in the UK men who have sex with men (MSM), while all HESNs in
Uganda were in heterosexual relationships. Concordance of responses between partners was determined. Each participant’s
sexual behavior score (SBS) was estimated based on the number and type of unprotected sex acts carried out in defined
time periods. Independent HIV acquisition risk factors (partner plasma viral load, STIs, male circumcision, pregnancy) were
integrated with the SBS, generating a RI for each HESN.
Results: 96 HIV serodiscordant couples completed 929 SBQs. SBSs remained relatively stable amongst the UK cohort, whilst
decreasing from Visit 1 to 2 in the Ugandan cohort. Compared to the Ugandan cohort, SBSs and RIs in the UK cohort were
lower at visit 1, and generally higher at later visits. Differences between the cohorts, with lower rates of ART use in Uganda
and higher risk per-act sex in the UK, had major impacts on the SBSs and RIs of each cohort. There was one HIV transmission
event in the UK cohort.
Conclusions: Employment of a risk quantification model facilitated quantification and comparison of HIV acquisition risk
across two disparate HIV serodiscordant couple cohorts.
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Introduction
The overall risk of sexual HIV transmission reflects the
frequency and nature of exposure to virus with different sex acts
confer varying risks of transmission [1–10]. In addition the
susceptibility of an HIV uninfected individual, and the infectious-
ness of their HIV seropositive partner contribute to transmission
risk [2]. The concept that certain rare individuals remain HIV
uninfected despite repeated sexual exposure to an HIV infected
partner has long been described [11–18]. Whilst HIV exposed
seronegative (HESN) individuals have provided extensive infor-
mation on the biology of HIV transmission, the relative and
specific contributions of host and viral factors underlying HIV
‘resistance’ remain unclear. The absence of a consistent definition
of HESNs and inclusion of well-defined control groups has
complicated comparisons both between and within studies [19].
Unanswered questions remain about the frequency, type of sex,
and duration of exposure required to define a HESNs phenotype.
Many studies of sexual behavior have focused on either men who
have sex with men (MSM) or heterosexual populations, and it is
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37727difficult to extrapolate or compare data from one to the other due
to differences in risk associated with, for example, vaginal or anal
intercourse [20].
Robust methodologies to quantify risk will facilitate a clear
definition of truly HESN cohorts. The primary goal of the
CHAVI002 study was to analyse immune parameters associated
with the HESN phenotype [21]. We report here on the secondary
goal of this study, which was to apply a detailed sexual behavior
questionnaire (SBQ) facilitating comparisons of reported behaviors
between HIV serodiscordant couples and HIV unexposed
seronegative (HUSN) controls in the context of detection of
HIV-specific immune responses. This SBQ, which details the
frequency and type of unprotected sex acts by couples, allows the
quantification of behavior based HIV-1 infection risk based on
population-level transmission data from serodiscordant couple
studies [20]. In the current study the SBQ was applied to two
diverse serodiscordant couple cohorts; a mostly MSM cohort
based in the United Kingdom, and a heterosexual cohort based in
Uganda. Sexual behavior analysis was coupled with clinical data to
build an HIV transmission risk index (RI) estimate for HESN
participants based on published literature [20]. Although the SBS
and RI generated as part of the CHAVI002 study was not found
to correlate with the detection of HIV-1 specific T cell responses
[21], analyses in the context of other immune parameters are
ongoing. The ability to improve the stratification of HESN within
cohorts, and compare levels of exposure between cohorts, will
allow an improved understanding of what immunological factors
play the most significant roles in resistance to HIV-1 infection, and
if such factors vary depending on the level and route of exposure.
Methods
Population Definitions
Two HIV serodiscordant couple cohorts were enrolled using the
same definition at: Imperial College NHS Trust London, UK, (24
serodiscordant, 14 HUSN couples) and MRC/UVRI, Entebbe,
Uganda (72 serodiscordant, 26 HUSN couples plus 3 HUSN
individuals). Potential participants were recruited through sexual
health clinics, local advertisements, and word of mouth. The study
protocol was approved by Division of AIDS, National Institutes of
Health and local ethics committees. All individuals enrolled gave
written informed consent. Condoms and risk reduction counselling
were given to all participants at each study visit; continued unsafe
sex practises were discouraged. Injection drug use was an
exclusion criterion whilst antiretroviral therapy (ART), pregnancy,
and breastfeeding were not. All participants were $18 years old.
HESN inclusion criteria were developed to ensure both minimal
levels and periods of exposure were met, while HUSN inclusion
criteria were developed to ensure individuals were sexually active
but at minimal risk of having been exposed to HIV-1 on any level
for at least 1 year.
Inclusion Criteria
HIV Serodiscordant Couples
N First sex act within the couple occurred $10 months prior to
screening
N $25 occasions of unprotected vaginal, anal, and/or oral sex
within the preceding 12 months
N The HIV infected partner was diagnosed $12 months prior to
screening
N HESN partner HIV-1 antibody and virus (NAT or p24
antigen) negative
Control HUSN Couples*
N Both partners HIV-1 antibody and virus (NAT or p24 antigen)
negative
N Free from sexually transmitted infections (STIs) at screening
N Monogamous sexual relationship for $12 months
N * In the Ugandan cohort, it was permitted for 1 individual of a
confirmed HUSN couple to enrol without their partner.
Although no data from such individuals were included in the
concordance, SBS, or RI analyses, samples were made
available for cellular studies.
Couples were followed for 4 study visits over 9 months. Data
collection, management and monitoring were undertaken by the
Statistical Center for HIV/AIDS Research & Prevention
(SCHARP).
HIV Testing
DetermineH HIV-1/2 point-of-care 3
rd generation immunoas-
say, and laboratory HIV NAAT assay (Micropathology Ltd., In-
house nested NAAT) were performed on all HIV uninfected
participants at each visit. Test standardisation was undertaken
using quality assurance panels (UKNEQAS in the UK and
UKNEQAS, CAP and VQA in Uganda). HIV plasma virus load
(pVL) (UK; Siemens Versant HIV-1 RNA 3.0 Assay, LOD; 50
copies/ml Uganda; Roche Amplicor v1.5 HIV test, LOD; 400
copies/ml), CD4 T-cell count (measured using FACS analysis),
and viral genotype were performed in the HIV+ participants.
STI Screening
Genital examinations and STI screens were offered at each
study visit. Any STI diagnosed was treated according to local
guidelines. Gonorrhoea and chlamydia PCR testing were
performed using the BD ProbeTec ET Strand Displacement
Amplification test on urine in men and endocervical sampling in
women. ELISA testing for syphilis, HSV-2 (UK only), and
hepatitis A, B, and C (Siemens ADVIA Centaur immunoassay)
were performed. Genital ulceration was diagnosed using ELISA
for syphilis and viral PCR for herpes.
Sexual Behavior Questionnaires (SBQs)
Individual, confidential, structured, paper SBQs were admin-
istered by one research nurse in the UK and 3 counsellors in
Uganda. They were collected at every visit, recording the total
number of protected and unprotected sex acts for the: past 3
months, past 7 days, and most sexually active week over the
preceding 3 months. These 3 time-frames were included for 2
reasons; firstly to allow an analysis of the concordance of responses
between the time windows, and secondly different time periods
were more appropriate for correlation with various immune
parameters. Six key sex acts, involving no condoms and
ejaculation, were further evaluated in this study: i) receptive anal
intercourse (RAI), ii) insertive anal intercourse (IAI), iii) insertive
vaginal intercourse (IVI), iv) receptive vaginal intercourse (RVI), v)
receiving oral intercourse (R-OI), and vi) giving oral intercourse
(G-OI).
Concordance of SBQ Responses between Study Partners
Concordance in SBQ responses was defined arbitrarily as a,3
fold difference in frequencies reported within a couple, or if one
partner gave an answer of 0, where the other answered ,3. Lack
of concordance in responses for 1 or more sex acts at a particular
visit excluded analysis of SBQ data from that couple for that visit.
CHAVI002 Cohorts Clinical Analyses
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Where concordance criteria were met, individual SBSs were
estimated over three time frames. SBS represents a composite of
frequency (n) of each unprotected (U) high risk sex act; URAI,
UIAI, UIVI, and URVI and is the sum of the number of times
each act was performed by the individual in the preceding time
frame, multiplied by the estimated per contact risk for the given
act, based on literature from HIV serodiscordant couple studies
[20]. Even though there is no per contact risk for the HUSN and
HIV+ participants, as their partners were HIV negative, their
SBSs were still calculated. This was used as a weighted marker for
the sex acts carried out, and is useful as a baseline measure of how
sexual behaviors change over time in the absence of a perceived
risk of infection, and how risk is distributed amongst serodiscor-
dant MSM couples.
SBS~(nURAI|0:005)z(nUIAI|0:00065)
z(nURVI|0:001)z(nUIVI|0:0005)
.
HIV Risk Index
An overall risk index (RI) was then estimated for each HESN
participant at each visit based on the previous 3 month period.
While in the current study the RI is not a reflection of the
probability of an HIV-1 transmission event occurring, it does
indicate the relative risk of transmission. The RI is the integration
of the SBS with known independent risk factors; partner HIV-
pVL, male circumcision status, pregnancy, and other STIs. This is
achieved by multiplication of the SBS based on relative risks and
odds ratios reported from HIV sero-discordant couple studies
[2,20]. Several potential risk factors were excluded from the
current study due to a lack of any incidences being reported
(infectious syphilis), all participants being the same for this factor
(stage of HIV infection), or a lack of consistent collection of
relevant data across study sites (HSV-2 serostatus, bacterial
vaginosis). The odds ratios used to generate the RI are outlined
in Table 1, and employed as outlined in the following formula.
RI~SBS|partnerHIVpVL|GUD|circumcision|pregnancy
.
Statistical Analyses
Two-sided Mann-Whitney tests with significance level of 0.05
were used to compare continuous variables between the two study
cohorts (e.g., CD4 counts, SBS). Two-sided Fisher’s exact tests
with significance level of 0.05 were used to compare response rates
(e.g., circumcision rates, ART use rates, STI rates, and the
proportion of MSMs). No adjustments were made for multiple
testing.
Results
Characteristics of Study Participants
Table 2 summarises the characteristics of the two cohorts
recruited. The HESN and HUSN groups are highly heteroge-
neous. In the UK cohort, HESN consist of 96% (23/24) MSMs
while HUSN are 36% (10/28) MSMs (p,0.0001), 32% (9/28)
heterosexual men, and 32% women. Ugandan couples reported
longer relationships (median 64, 74 months) for serodiscordant
and HUSN couples respectively than in the UK (median 23, 39
months). A greater proportion of HIV+ individuals in the UK
were on ART at visit 1 (70.8% UK, 34.7% Uganda, p=0.004).
Median CD4+ T cell counts were higher in the UK (560 cells/cc)
than Ugandan cohort (234 cells/cc) at enrolment (p,0.0001).
HIV-pVLs were much lower in the UK (median=LOD=,50
copies/cc) than in Uganda (median=7,290 copies/cc). There was
a lower rate of male circumcision amongst HESNs in the UK
cohort (8%) compared to those in Uganda (47%) but this
difference was not statistically significant (p=0.22). The differ-
ences in circumcision rates for the HIV+ and HUSN groups were
also not significant though rates were lower in the UK than in
Uganda (9% vs 26% with p=0.11 and 16% vs 38% with p=0.12
respectively). There was a significantly higher prevalence of STIs
observed in the Ugandan cohort, particularly in the HUSN group,
where only 1/24 (4%) of UK HUSNs but 23/55 (42%) of Uganda
HUSNs had any non-HIV STIs at any study visit (p=0,0.0005).
This difference is due to higher rates of bacterial vaginosis and
candidiasis, in Uganda neither of which were reported in the UK
cohort. Of the 23 HUSNs with episodes of STIs in Uganda, 18
reported bacterial vaginosis and/or candidiasis and no other STIs.
SBQ Responses
A summary of the key reported SBQ responses for visit 1 is
presented in Table 3. There was a wide range of reported sexual
practices amongst all cohorts enrolled. Of note, there was no anal
and limited oral intercourse reported, irrespective of risk group, in
the Ugandan cohort.
Concordance of SBQ
Concordance of SBQ answers reflects the agreement in
partners’ responses for each specific time period; results for visit
1 are provided in Table 3. Concordance was higher when oral sex
questions were excluded. Concordance generally improved at later
visits, with Visit 4 concordance reaching 93% (14/15) for UK
serodiscordant couples’ responses for the past 3 months excluding
oral sex questions (11/11=100% for HUSN couples) and 93%
(43/46) for Ugandan serodiscordant couples (16/19=84% for
HUSN couples).
Comparisons of SBS for Projected and Observed Last
3 Month Data
To evaluate the agreement in reported behavior over different
time frames, we compared the SBS based on the projected 3
month data (last 7 days multiplied by 13) to the SBS based on the
Table 1. The risk factors and odds ratios used to generate the
risk index (RI) in the current study.
Factor HESN susceptibility HIV+ infectiousness
Viral load (Log10)
0–3.49 1
3.50–4.16 5.8
4.17–4.88 6.91
.4.88 11.87
Male circumcised 0.47 1
GUD 2.58 2.04
Pregnancy 2.16 1
doi:10.1371/journal.pone.0037727.t001
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data for both time frames. Overall, there is good agreement
between the observed and projected 3 month SBSs (data not
shown). However, the most significant observation was that for
individuals where the number of sex acts in the past 7 days is low
or zero, the projected 3 month SBS may not accurately reflect the
3 month exposure. In view of these discrepancies on an individual
level, RI estimates were generated based on the observed 3 month
SBS.
Sexual Behavior Scores Over Preceding 3 Month Period
In the UK cohort, median SBSs for HESNs at Visit 1 was
0.003575 (range 0–0.036), 0.01130 (range 0–0.0678) for HUSNs
and 0.02065 (range 0–0.25195) for HIV+ individuals. The highest
SBS over all visits was 0.126 for HESNs (Visit 3), 0.165 for
HUSNs (Visit 3), and 0.25195 for HIV+s (Visit 1). For both
cohorts, visit 1 is the most relevant time point here, because it
represents the baseline sexual behavior not yet influenced by safe
sex counselling. There was some indication of a lowering of SBS
over time in both the HESN and HIV+ groups, while HUSN SBSs
remained more constant over time (Figure 1). Interpretation of a
numerical value given for SBS is demonstrated using a represen-
tative individual with an initial high SBS (e.g. 0.25195) reflected 53
sex acts over the preceding 3 month period. For the same
participant at another visit a SBS of 0.2315 represented 55 sex
acts. Despite a slightly increased number of reported unprotected
sex acts at this visit, the lower SBS reflects an increasing
proportion of insertive rather than receptive sex acts.
In the Ugandan cohort, median SBS for HESN at Visit 1 was
0.00850 (range 0–0.075), 0.02350 (range 0–0.048) for HUSNs,
and 0.00800 (range 0–0.0600) for the HIV+ individuals. In all
study groups, there was a marked decrease in the SBS between
visit 1 and visit 2 (Figure 1). A representative high SBS (0.076) was
a female HESN reporting 76 unprotected vaginal sex acts over the
preceding 3 month period.
There was a statistically significant difference (Mann Whitney
tests) in SBS between the UK and Ugandan cohort for HESNs at
Visits 2, 3, 4 (p=0.044, 0.020, 0.023 respectively), for HUSNs at
Visits 1 and 4 (p=0.007 and 0.003), and for HIV+s at visits 2, 3, 4
(p=0.038, 0.0002, 0.004), with the UK cohorts having higher
SBSs across the HESN and HIV+ groups, and lower SBSs
amongst the HUSN group.
HESN Risk Index
Median RIs at visits 1, 2, 3, and 4 in the UK were 0.00663,
0.00305, 0.00195, and 0.00221, ranging over all visits from 0–
0.126. Median RI at visit 1 in Uganda was 0.01949 and 0 at all
later visits, ranging over all visits from 0–0.66472. The addition
of HSV sero-status for the UK participants increased the RIs of
HSV-2 seropositive participants (data not shown) but was not
included in these analyses due to a lack of data from the Uganda
cohort.
Figure 2 illustrates the overall RIs for all HESN participants for
both Ugandan and UK participants over time in study. The
relatively increase in RIs compared to SBSs seen at visit 1 in the
Ugandan cohort compared with the UK demonstrates the impact
of HIV+ partners’ pVL and pregnancy. After visit 1 it can be seen
that the RI of UK HESN is higher than the Ugandan HESNs, due
to a decrease in Ugandan SBSs.
RI of Individual UK HESN Who Seroconverted
One HESN seroconverted between visits 1 and 2, and matched
viral genotyping confirmed transmission from their study partner.
For this participant the estimated SBS for visit 1 was 0.00065, and
their partner’s pVL was 18 751 copies HIV RNA/ml, giving a RI
of 0.00449.
Table 3. Data from visit 1 summarising key sexual behavior acts (with ejaculation and no condom use) reported within the past 3
months and the proportion of couples who were concordant in their responses across all sex acts.
UK Uganda
HESN n=24 HIV+ n=24 HUSN n=28 HESN n=72 HIV+ n=72 HUSN n=55
Insertive anal intercourse median
(range)
6 (0–40) 0 (0–3) 3 (0–12) NR
a NR NR
Receptive anal intercourse median
(range)
0 (0–2) 4 (0–50) 3.5 (0–38) NR NR NR
Vaginal intercourse median (range) 3
b 12
b 19 (0–36) 12 (0–150) 12 (0–524) 30 (0–48)
Received oral sex median (range) 2 (0–24) 0 (0–50) 3.5 (0–30) 1 (0–14) 9 (0–24) 4 (0–42)
Gave oral sex median (range) 0 (0–36) 1 (0–50) 4 (0–30) 2 (0–18) 1 (0–3) 2 (0–42)
Concordance of responses HESN/HIV+24 couples HUSN 14 couples HESN/HIV+72 couples HUSN 25 couples
Past 7 days
With oral 20/20 (100%) 13/13 (100%) 28/32 (88%) 22/22 (100%)
Without oral 20/20 (100%) 13/13 (100%) 29/30 (97%) 22/22 (100%)
Past 3 months
With oral 12/24 (50%) 8/14 (57%) 55/69 (80%) 19/25 (76%)
Without oral 19/24 (79%) 11/14 (79%) 58/69 (84%) 20/25 (80%)
Most active week
With oral 20/24 (83%) 13/13 (100%) 64/70 (91%) 25/25 (100%)
Without oral 20/24 (83%) 13/13 (100%) 64/70 (91%) 25/25 (100%)
aNR; none reported.
bSingle data point only.
doi:10.1371/journal.pone.0037727.t003
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Whilst the development of risk evaluation models remains
controversial [22,23] the absence of an internationally agreed
definition of HESN necessitated a pragmatic definition of the two
cohorts for this study. We have shown that a similarly structured
SBQ can be used in conjunction with clinical data to allow
comparison of HIV-1 exposure between two very different HESN
cohorts; a primarily MSM cohort from the UK and an entirely
heterosexual cohort from Uganda. Rigorous enrolment criteria
were used to maximise the levels of exposure defining HESNs in
this study, Analysis of the SBS and RI describes a wide
heterogeneity in the levels of relative HIV-1 exposure for
individual HESN participants, both between and within cohorts.
This was largely influenced by differences in sexual behaviors
(including the type and frequency of sex acts), pVLs and ART use
in seropositive partners. This heterogeneity underpins much of the
controversy of immunological data in the HESN field [11–18].
The main goal of the CHAVI002 study was to characterise
HIV-specific immune responses amongst HESNs and HUSNs
[21]. For this reason enrolment of appropriate matched for sexual
Figure 1. Sexual behavior scores (SBSs) across visits for study groups in the UK
1 (top row) and Uganda (bottom row) cohorts.
Boxplots of SBSs of concordant individuals are shown, where the midline and box represent the median 6 the 25th and 75th percentiles; whiskers
extend to the extreme data points that are #1.5 times the interquartile range. Extreme outliers are indicated by circles.
1Note that the scales of the y-
axis for UK HIV+ and HUSN are much larger than those of the other groups. *One UK HESN with a very large SBS at Visit 3 (0.126) is not shown in order
to maintain a comparable scale over plots where possible.
doi:10.1371/journal.pone.0037727.g001
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critical to allow definitive comparison in immunological outcome
measures. However, despite these important goals, the enrolment
of suitable HUSN couples was challenging, necessitating protocol
amendments. Difficulties in enrolling monogamous MSM HUSN
couples were encountered in the UK. In Uganda although many
HUSN couples expressed an interest in the study, both partners
did not always agree to participate.
Sexual behavior reported through a SBQ is often confounded
by bias introduced by participant’s wish to please, recall bias, and
interviewer bias [24–26]. The use of self-completed or computer-
led SBQs (e.g. CASI) can circumvent some of these specific issues
but have their own potential to introduce bias [27,28]. The
absence of reported anal intercourse amongst the Ugandan
participants across all 3 risk groups was unexpected [10,29–32],
as other African studies populations reported 1 in 50 heterosexual
sex acts involved anal sex [31]. This may be linked to discomfort
about the practice among interviewers and participants and the
belief that anal intercourse represents homosexual practice. In our
analyses it is not possible to account for bias in sexual behavior
reporting. The data from visit 1 represents the most accurate
representation of pre-study sexual behavior, and subsequently
practices altered, mostly reducing risk. We would recommend
removing questions relating to ‘the week of most activity’ as this
time frame was poorly defined, and often misinterpreted by
couples leading to discrepant responses. Similarly poor concor-
dance between partners in reported oral sex act frequency led to its
removal in calculating the SBS and RI. This may reflect difficulties
in interpreting relevant questions, as oral sex may form an integral
part of the main penetrative sex act rather than a separate act
itself. The recent linkage of reported oral exposure with systemic
immunological outcomes [18] suggests that oral sex practices are
valuable in evaluating overall risk behaviors.
The rates of STIs may be underestimated in the Ugandan
cohort as, although STI screens were offered to all participants
only 33% of participating individuals consented to full STI
screening at every study visit. Many diagnoses were based on self-
reported symptoms, especially of genital ulcer disease (GUD) and
for this reason GUD was excluded as a factor when estimating the
overall RIs for all HESNs in this study. If such a tool were to be
utilised in the future, we would recommend the incorporation of
GUD screening. HSV-2 serology was performed for UK HESNs
only, hence the Uganda RIs could not incorporate HSV-2
serostatus information and thus this factor was not considered in
this study but could be in future ones. There are several other
factors that have not been included in the RI in this study such as
genetic [13], immunological [11–18], and viral characteristics
[2,10,33,34], and sex outside the primary relationship. Overall,
the exclusion of these factors means that the RIs reported may be
an underestimate of the true risk of HIV-1 transmission.
The decision to focus SBS and RI estimates and comparisons on
sex acts reported for the previous 3 month period was based upon
the greater biological applicability of this data to adaptive immune
responses and thus the primary goal of the CHAVI 002 study;
analysis of T-cell responses [21]. Analyses based on sexual
exposure over the preceding 7 days may be more relevant to
studies examining innate and/or mucosal immunity [35].
SBS estimates from visit 1 most accurately represent sexual
exposure prior to enrolment into the study. The observed decrease
in SBSs over time amongst the Ugandan HESN may result from
Figure 2. Risk indexes (RIs) for HESN participants in the UK and Ugandan cohorts over 4 visits. RIs were generated based on reported
sexual behaviors for the last 3 months (if concordant with answers from the HIV+ study partner), partner HIV-1 pVL, concurrent STIs, male
circumcision status, and pregnancy. Boxplots of RI are shown, where the midline and box represent the median 6 the 25th and 75th percentiles;
whiskers extend to the extreme data points that are #1.5 times the interquartile range. Extreme outliers are indicated by circles.
doi:10.1371/journal.pone.0037727.g002
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screening. The relative stability in SBSs amongst the HESN MSM
population in the UK could reflect a longer history of safe sex
awareness in this group, meaning the unsafe acts occurring prior
to visit 1 were not due to ignorance, and reinforced by repeated
HIV negative test results. This is supported by the differences in
the UK HESN and HIV+ SBSs, with the later group having
approximately 5 fold higher scores, suggesting behavioral risk
stratification being employed by these serodiscordant couples.
However, the one HIV transmission observed during this study
illustrates the danger of ambivalence to unsafe sexual practices
within high risk populations. Appropriate individualised safe sex
counselling remains critical for each HESN and is key to delivering
lasting behavior changes. The apparent resistance to such
messages in the UK MSM cohort indicates that in the future
more innovative methods for delivery of safe sex messages should
be implemented [36].
The development of the RI model to evaluate relative risk of
HIV acquisition in the context of HIV serodiscordant couples has
been previously outlined in detail [20]. The quality of all models is
dependent on the validity of the underlying assumptions and
accuracy of the supporting data used to develop it. The absolute
value for each individual HESN RI represents their overall
modelled risk of HIV acquisition for a specific time period. For this
RI model the supporting evidence was derived from published
clinical data from HIV serodiscordant couple studies. More recent
estimates of transmission risk suggest a 20-fold greater risk for anal
than vaginal intercourse [10], which is greater than the difference
in the RI model used here, and a strong decrease in transmission
risk related to early ART intervention [37] suggesting that RI
models should be subject to ongoing review as more informative
data becomes available. Issues with answers to questions relating
to oral sex, the lack of information gathered on sex outside the
primary relationship, and the exclusion of other factors that can
influence risk, such as HSV-2 sero-status, could have led to an
underestimation of RIs. For the purposes of this paper, the RIs
were mainly of interest for cross-cohort and longitudinal compar-
isons rather than an absolute measure of risk. However, for
comparisons across cohorts one must be aware of the potential for
differences in reporting sexual behavior; it is not possible to
account for this. Without validation against empirical data, one
cannot know whether the proposed risk index is reasonable, either
in absolute terms (making inferences about an individual’s
probability of acquiring HIV) or in relative terms (comparing
acquisition risks in heterosexual men, heterosexual women and
MSM). Future work to validate this model is proposed, from
transmissions recorded through couple studies [37]. This study
highlights that a SBS/RI approach can be used to quantify relative
risk in HESN cohorts, and that such risk can be highly
heterogeneous even when strict enrolment criteria are used.
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